Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Authors: Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li‐Tzong Chen, Masayuki Kitano, Choong‐kun Lee, Jin Won Kim, Ming‐Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen‐Shi Chen, Piotr Potemski, Howard A. Burris, Vikas Ostwal, Suebpong Tanasanvimon, Chigusa Morizane, Renata Zaucha, Mairéad G. McNamara, Antonio Avallone, Juan E Cundom, В. В. Бредер, Benjamin Tan, Satoshi Shimizu, David Tougeron, Ludovic Evesque, Mila Petrova, David B. Zhen, Roopinder Gillmore, Vineet Gupta, Farshid Dayyani, Joon Oh Park, Gary L. Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W. Valle - The Lancet 2024 cited by 254